ArticleCancer immunology, immunotherapy : CII2025

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).

Matteo Santoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.